Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double- Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 Mg QD and 50 Mg QD Doses in Patients Infected With Hepatitis B Virus

NCT00305019 is registered in ClinicalTrials.gov with Bukwang Pharmaceutical as lead sponsor.

NCT NCT00305019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00305019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double- Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 Mg QD and 50 Mg QD Doses in Patients Infected With Hepatitis B Virus
Lead sponsor
Bukwang Pharmaceutical
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2002
Completion date
March 31, 2004
Enrollment
120
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b